Alpha 2.0
Login Register
» Authors » Robert McQuade

Robert McQuade

Explore the profile of Robert McQuade including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 709
Followers 0
Related Specialties
Psychiatry
Pharmacology
Pediatrics
Top 10 Co-Authors
Raymond Sanchez
William Carson
Ronald Marcus
Robert A Forbes
Raymond Mankoski
Joan Zhao
William H Carson
George Manos
Stephen Wright
Eva Kohegyi
Published In
J Affect Disord
J Child Adolesc Psychopharmacol
J Psychopharmacol
J Psychiatr Pract
J Am Acad Child Adolesc Psychiatry
Affiliations
Soon will be listed here.
Recent Articles
1.
Shattering the Shield: Embracing Complexity in Undergraduate Medical Education
Bezzina C, McQuade R, Lowe W, Mair F, Pope L
Clin Teach . 2025 Jan; 22(1):e70018. PMID: 39832492
Background: Multimorbidity and patient complexity are increasing, yet undergraduate medical education curricula remain dominated by single disease frameworks, where students are often shielded from exposure to this complexity. Why this...
2.
Evaluating the impact of a Risk Evaluation and Mitigation Strategy with tolvaptan to monitor liver safety in patients with autosomal dominant polycystic kidney disease
Estilo A, Tracy L, Matthews C, Riggen M, Stemhagen A, Wilt T, et al.
Clin Kidney J . 2023 Feb; 15(8):1553-1561. PMID: 36824061
Background: On approval of JYNARQUE (tolvaptan) for use in patients with autosomal dominant polycystic kidney disease (ADPKD) at risk for rapid progression, the US Food and Drug Administration required a...
3.
Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials
Adler L, Adams J, Madera-McDonough J, Kohegyi E, Hobart M, Chang D, et al.
J Clin Psychopharmacol . 2022 Jun; 42(5):429-439. PMID: 35652746
Purpose/background: Centanafadine is an inhibitor of norepinephrine, dopamine, and serotonin reuptake transporters under investigation for the treatment of attention-deficit/hyperactivity disorder (ADHD). Methods/procedures: Two phase 3 randomized, double-blind, placebo-controlled, parallel-group studies...
4.
Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain
Lichtman A, Lux E, McQuade R, Rossetti S, Sanchez R, Sun W, et al.
J Pain Symptom Manage . 2017 Sep; 55(2):179-188.e1. PMID: 28923526
Context: Prior Phase 2/3 studies found that cannabinoids might provide adjunctive analgesia in advanced cancer patients with uncontrolled pain. Objectives: To assess adjunctive nabiximols (Sativex), an extract of Cannabis sativa...
5.
Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study
Correll C, Kohegyi E, Zhao C, Baker R, McQuade R, Salzman P, et al.
J Am Acad Child Adolesc Psychiatry . 2017 Aug; 56(9):784-792. PMID: 28838583
Objective: To evaluate the efficacy, safety, and tolerability of aripiprazole, a dopamine D receptor partial agonist, as maintenance treatment in adolescent outpatients with schizophrenia. Method: This was a multicenter, double-blind,...
6.
Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies
Fallon M, Lux E, McQuade R, Rossetti S, Sanchez R, Sun W, et al.
Br J Pain . 2017 Aug; 11(3):119-133. PMID: 28785408
Background: Opioids are critical for managing cancer pain, but may provide inadequate relief and/or unacceptable side effects in some cases. Objective: To assess the analgesic efficacy of adjunctive Sativex (Δ-tetrahydrocannabinol...
7.
Randomized, Double-Blind, Placebo-Controlled Trial Demonstrates the Efficacy and Safety of Oral Aripiprazole for the Treatment of Tourette's Disorder in Children and Adolescents
Sallee F, Kohegyi E, Zhao J, McQuade R, Cox K, Sanchez R, et al.
J Child Adolesc Psychopharmacol . 2017 Jul; 27(9):771-781. PMID: 28686474
Objectives: Aripiprazole modulates dopaminergic and serotonergic pathways that may play a role in the pathogenesis of Tourette's disorder (TD). This trial evaluated the efficacy and safety of oral aripiprazole in...
8.
Stepping Back From Crisis Points: The Provision and Acknowledgment of Support in an Online Suicide Discussion Forum
Wiggins S, McQuade R, Rasmussen S
Qual Health Res . 2016 Mar; 26(9):1240-51. PMID: 26935723
Suicide is a global health concern, though little is known about the social practices that might support those who are contemplating suicide. Online forums provide a unique insight into the...
9.
Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change
Mankoski R, Stockton G, Manos G, Marler S, McQuade R, Forbes R, et al.
J Child Adolesc Psychopharmacol . 2013 Oct; 23(8):572-6. PMID: 24138011
Objective: The purpose of this study was to evaluate the impact of prior antipsychotic exposure (PAE) on safety and tolerability outcomes in pediatric subjects receiving aripiprazole treatment. Methods: This study...
10.
Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study
Mallikaarjun S, Kane J, Bricmont P, McQuade R, Carson W, Sanchez R, et al.
Schizophr Res . 2013 Jul; 150(1):281-8. PMID: 23890595
This 24-week, open-label, Phase Ib, parallel-arm, multiple-dose trial assessed the pharmacokinetics, safety and tolerability of a once-monthly injection of aripiprazole (aripiprazole once-monthly) in 41 subjects with schizophrenia. The objective was...